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A phase II clinical trial of intrapleural paclitaxel injection for malignant effusions of non-small-cell lung cancer 
(NSCLC) was conducted in order to evaluate the efficacy and toxicity profile of paclitaxel pleurodesis in patients 
with malignant effusions. From February to May of 1996, 15 NSCLC patients with malignant pleural effusions were 
enrolled on study. After adequate drainage and assurance of lung re-expansion, paclitaxel 125 mg m-’ diluted in 
normal saline was infused through a preinserted pig-tail catheter which was removed 2 h later. Chest radiography 
and sonography were scheduled 4 days later; depending on whether there remained a significant amount of pleural 
effusion, further drainage by needle thoracentesis or by a pig-tail catheter was performed. 
All patients were assessable for toxicity. Ipsilateral chest and/or shoulder pain, fever, facial flushing and nausea 
were the most frequent side-effects. Grade 4 neutropenia, grade 3 anaemia, and grade 3 renal impairment occurred 
in one patient each. Fourteen patients were evaluable for response at the end of the fourth week. Overall response 
rate of pleural effusion in evaluable patients was 92.9%, with a complete response rate of 28.6%. There was one out 
of 14 evaluable patients whose measurable tumour lesion decreased by more than 50% (partial response). No disease 
progression was noted among evaluable patients at the end of the fourth week. It is concluded that paclitaxel is a 
useful agent for the treatment of malignant pleural effusions. Because of its relatively low systemic toxicity, 
intrapleural paclitaxel injection in combination with systemic chemotherapy or radiotherapy can be considered in 
treating NSCLC patients with malignant pleural effusions. 
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Introduction 
Malignant pleural effusion is a common and significant 
problem in advanced cancer. Lung cancer is the leading 
cause of malignant pleural effusion (14). When patients 
with lung cancer are first evaluated, about 15% have a 
pleural effusion (3,5). During the disease course of lung 
cancer, at least 50% of patients with disseminated lung 
cancer develop a pleural effusion (5). The presence of 
pleural effusion in patients with non-small-cell lung cancer 
(NSCLC) usually indicates advanced disease and portends 
a grave prognosis. In contrast to breast cancer or lym- 
phoma, NSCLC is usually refractory to chemotherapy, and 
thus the most common therapy for these NSCLC patients 
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with malignant pleural effusions is a tube thoracostomy and 
intrapleural instillation of a sclerosing agent to obliterate 
the pleural space and to prevent reaccumulation of the 
effusion. Previously, tetracycline was recommended as the 
agent of choice for chemical pleurodesis. Because of its 
unavailability in parenteral form, the derivatives mino- 
cycline and doxycycline have been substituted. Other 
frequently recommended agents are talc, Corynebacterium 
parvum, and the antineoplastic agent bleomycin (6,7). 
There has been a recurring interest in using intracavitary 
chemotherapy for malignant ascites or pleural effusions 
because of its potential ability to treat the underlying 
malignancy in addition to providing local control of the 
effusion. Chemotherapeutic agents that have been adminis- 
tered in the past include nitrogen mustard, doxorubicin, 
bleomycin, methotrexate, mitoxantrone, 5-fluorouracil, 
cisplatin, carboplatin, melphalan, mitomycin, cytarabine, 
etoposide, etc (8-11). Except for cisplatin, most of these 
chemotherapeutic drugs are ineffective when given for 
NSCLC. 
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Paclitaxel (Taxol), the first of the taxane antimicrotubule 
agents isolated from the Western Yew, is a new anticancer 
agent that has demonstrated efficacy in the treatment of 
ovarian, breast and lung cancer (12-17). It is a novel 
chemotherapeutic agent which has a single-drug response 
rate of 21-24% in NSCLC (16,17). Results of a phase I 
clinical trial of intraperitoneal paclitaxel showed that pacli- 
taxel can be delivered by the intraperitoneal route with 
minimal toxicity with a major pharmacokinetic advantage 
(18). The experience with intrapleural paclitaxel chemo- 
therapy has been relatively rare. We previously performed a 
phase I intrapleural paclitaxel injection trial on patients 
with malignant pleural effusion, which found that maximal 
tolerated intrapleural paclitaxel injection dose was 225 mg 
m -’ and dose-limiting toxicity involved the development 
of severe dyspnoea (19). It was found that taxol 125 mg 
m ~ 2 was effective for pleurodesis in patients who received 
this level of dosage. This report is of a phase II clinical trial 
of intrapleural paclitaxel injection (125 mg m-2) to deter- 
mine the efficacy of effusion control in NSCLC patients 
with malignant pleural effusion and to determine the 
toxicity profile of this kind of treatment. The result of 
this kind of treatment was promising and without severe 
side-effects. 
Materials and Methods 
The primary objective of this study was to evaluate the 
efficacy of paclitaxel pleurodesis, including symptom relief 
and prevention of reaccumulation of effusions. The second 
objective was to evaluate the side-effects accompanying this 
kind of treatment. Whether there exist systemic anti- 
tumour effects in addition to pleurodesis was also assessed. 
Patients were eligible for this study if they had sympto- 
matic, cytologically proven malignant pleural effusion of 
NSCLC. No prior intrapleural therapy was allowed. Radio- 
therapy, systemic chemotherapy and hormonal therapy 
were also not allowed within 4 weeks prior to trial entry. 
However, radiotherapy, chemotherapy and/or hormonal 
therapy can be given 4 weeks after intrapleural paclitaxel 
treatment. Adequate liver, renal and hematological func- 
tion were required for study entry. The parameters used 
for this were (1) total serum bilirubin I 1.5 mg%, (2) 
serum creatinine 12.0 mg dl~ ’ and (3) peripheral blood 
granulocyte count 2 1500 mm- 3 and platelet count 
2 lOO*OOO mm- 3. Patients must be 18 years of age or older. 
A life expectancy of 2 months or longer and a performance 
status of O-2 on the Zubrod scale after effusion drainage 
were required. This trial was approved by the hospital 
ethics committee and informed consent was obtained from 
all patients before study entry 
All patients were required to be admitted to the hospital 
and to have a pig-tail catheter inserted. A chest roentgeno- 
gram to confirm lung re-expansion after catheter drainage 
is needed. This X-ray film after adequate catheter drainage 
was to serve as the baseline for follow-up evaluation of 
recurrence of effusion. A drainage rate less than 150 ml 
(24 h - ‘) was required. All patients received premeditation 
for paclitaxel treatment, including dexamethasone 20 mg 
orally 12 and 6 h prior to’ paclitaxel treatment, diphen- 
hydramine 50 mg intravenous infusion 45 min prior to 
paclitaxel treatment, and cimetidine 300 mg intravenous 
infusion 30 min prior to paclitaxel treatment. Then, paclit- 
axe1 125 mg m - 2 was diluted in normal saline to a concen- 
tration of 0.6 mg ml - ’ (27G320 ml) and instilled into the 
pleural cavity through the pig-tail catheter. After paclitaxel 
instillation, the pig-tail catheter was clamped for 2 h and 
then removed. Patients were asked to change position at 
15 min intervals during this 2 h period in order to ensure 
good dispersion of the drug throughout the pleural space. 
Chest roentgenography and ultrasonography were done 
after 96 h to assess the initial response of pleural effusion to 
treatment, If there was no obvious effusion remaining, no 
further management was given and the patient was dis- 
charged. If there was a small amount of effusion remaining, 
sono-guided needle aspiration of the remaining fluid was 
performed. If there was a moderate to large amount of 
effusion remaining, pig-tail catheter drainage was per- 
formed and drainage was continued until daily drainage 
was under 100 ml, and the tube was removed. The purpose 
of retention of paclitaxel in the pleural cavity for 96 h or 
longer was to allow the chemotherapeutic effect to occur by 
prolonged contact of paclitaxel with pleural space. Patients 
were evaluated for toxicity during hospitalization, and 
every 2 weeks after discharge for 8 weeks, and then monthly 
for 6 months. Thereafter, patients were evaluated every 3 
months. Toxicity was graded according to the U.S. 
National Cancer Institute Common Toxicity Criteria. 
Chest roentgenograms were obtained monthly to assess 
reaccumulation of the pleural effusion. A follow-up chest 
CT scan was performed at 4 weeks after paclitaxel treat- 
ment if initial measurable lesions were evaluated by CT 
scan. Chest ultrasonography was done if reaccumulation of 
effusion could not be ascertained by chest radiography or 
loculated effusion was suspected. All the chest X-ray films 
taken in this study were obtained with the standard 
posterior-anterior view. All the radiological examinations 
were performed under the monitoring of a radiologist not 
involved in the study. The single-blind method was used in 
follow-up chest radiograph evaluation by physicians and 
radiologists. 
The treatment response of malignant effusion was evalu- 
ated according to the following criteria: (1) complete 
response (CR), no fluid reaccumulation and patients were 
free of symptoms for at least 4 weeks as determined by chest 
radiography, ultrasonography and/or CT scan and clinical 
evaluation; (2) partial response (PR), recurrence of effusion 
to less than 50% of the original effusion volume, patients 
were asymptomatic and no need for thoracentesis for 
symptom relief within 4 weeks after treatment; (3) failure, 
recurrence of effusion greater than 50% of the original 
volume, patients were symptomatic and need for thoracen- 
tesis to relieve symptoms within 4 weeks of treatment. 
Objective treatment response of malignant effusion 
included CR and PR. The criteria for main tumour lesion 
response to intrapleural paclitaxel treatment were as 
follows: (1) CR, the disappearance of all known disease for 
at least 4 weeks after treatment; (2) PR, at least a 50% 
decrease in total tumour size of the lesions that had been 
TABLE 1. Clinical characteristics of patients with non-small- 
cell lung cancer with malignant pleural effusion 
Characteristic 
Number of 
patients % 
Sex 
Male 8 53.3 
Female I 46.7 
Age (years) Mean 64.1, range 47-78 
Performance status 
1 4 26.7 
2 10 66.7 
3 1 6.6 
Histology 
Adenocarcinoma 13 86.6 
Epidermoid carcinoma 1 6.7 
Carcinoma, poor1 1 6.7 
differentiated 
Stage 
IIIB 10 66.7 
IV 5 33.3 
Prior treatment 
No 7 46.1 
Radiotherapy 3 20 
Repeated thoracentesis 5 33.3 
measured before treatment at 4 weeks after intrapleural 
chemotherapy and, in addition, there must be no appear- 
ance of new lesions, progression of any other lesion or 
failure of effusion treatment; (3) minor response (MR), a 
25-50% decrease in total tumour size of the lesions that 
had been measured before treatment at 4 weeks after 
intrapleural chemotherapy and, in addition, there may be 
no appearance of new lesions, progression of any lesion or 
failure of effusion treatment; (4) stable disease (SD), a 25% 
decrease in tumour size cannot be established, nor is a 25% 
increase in the size of one or more measurable lesions 
demonstrated at 4 weeks after treatment; (5) progressive 
disease (PD), at least a 25% increase in size of at least one 
measurable lesion or the appearance of new lesions. 
Results 
From February 1996 to May 1996, 15 NSCLC patients 
with malignant pleural effusions were enrolled on study. 
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There were eight men and seven women. The average age 
was 64 years (range, 47-78 years). The clinical characteris- 
tics of these 15 patients are shown in Table 1. The majority 
of patients had an initial performance status scale of 1 or 2. 
Adenocarcinoma was the most common cell type and was 
seen in 13 patients. One patient had epidermoid carcinoma 
and another poorly differentiated carcinoma that could not 
be further characterized. All patients were chemotherapy 
naive. Only three patients received prior radiotherapy for 
control of primary NSCLC lesions. Five of 15 patients had 
a history of repeated thoracentesis. 
Pig-tail drainage of effusion was done in all patients 
before intrapleural paclitaxel injection. From 3 to 14 days 
(median 7 days) drainage was needed before paclitaxel 
could be given. After intrapleural paclitaxel injection for 
96 h, there were five patients who needed pig-tail reinser- 
tion. Four patients received thoracentesis only. The remain- 
ing six patients received no further management because 
chest radiography and sonography showed no evidence of 
obvious residual effusion (Table 2). Three patients had 
follow-up effusion cytology on day 5 and the results were 
negative for malignant cells in two patients and marked 
degeneration of tumour cells in one patient. Five patients 
had effusion cell count and differential count follow-up on 
day 5 and all showed a marked increase in neutrophil count 
with a reversal of lymphocyte predominance to neutrophil 
predominance. 
All patients were assessable for toxicity. The toxicities are 
shown in Table 3. Seven patients (46.7%) suffered from 
ipsilateral chest or shoulder pain which could be relieved by 
non-steroid anti-inflammatory drugs or codeine. It usually 
occurred several hours after intrapleural paclitaxel injection 
and subsided 3 or 4 days later. Alopecia occurred only in 
one (6.7%) patient. Grade 1 or 2 nausea occurred in seven 
patients (46.7%). Grade 2 vomiting occurred in only one 
(6.7%) patient. Fever occurred in five patients. Among these 
five patients, four patients had no evidence of infection and 
the remaining patient suffered from febrile neutropenia. 
The duration of fever was l-5 days with a median of 2 days. 
Concerning myelosuppression, only one patient suffered 
from grade 4 neutropenia (neutrophils ~500 u 1 - ‘). There 
was also one patient who suffered from grade 2 thrombo- 
cytopenia, two patients had grade 1 anaemia and one 
patient had grade 3 anaemia (haemoglobin between 6.55 
7.9 g dl ~ ‘). One patient suffered from grade 3 renal func- 
tion impairment (serum creatine between 3.1 and 6.0 times 
normal range) and grade 2 liver function impairment. This 
patient, who suffered from renal and liver function impair- 
ment, deteriorated rapidly and died on the 14th day after 
TABLE 2. Effusion management at 96 h after intrapleural paclitaxel treatment 
Patient number 
Amount drained, mean (range) 
Days on pig-tail, mean (range) 
Pig-tail 
reinsertion 
5 
6 (2-12) 
Thoracentesis 
4 
480 (150-1060) 
No further 
management 
6 
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TABLE 3. Toxicity in patients with non-small-cell lung cancer with malignant pleural effusion after 
paclitaxel intrapleural therapy 
Type of toxicity 
Grade 1 Grade 2 Grade 3 Grade 4 
W> (“4 (%I (%I 
Chest and/or should pain 
Alopecia 
Nausea 
Vomiting 
Fever 
Without neutropenia 
With neutropenia 
Myelosuppression 
Neutropenia 
Thrombocytopenia 
Anaemia 
Renal 
Hepatic 
6.7 40 0 0 
6.7 0 0 0 
33.3 13.3 0 0 
0 6.7 0 0 
0 26.7 0 0 
0 6.7 0 0 
0 0 0 6.7 
0 6.7 0 0 
13.3 0 6.7 0 
0 0 6.7 0 
0 13.3 0 0 
TABLE 4. Chest radiographic findings of 14 evaluable patients before and 4 weeks after intrapleural 
paclitaxel therapy 
Findings* 
drainage 
Before 
Before 
paclitaxel 
injection 
Number of patients (%) 
96 h after 
paclitaxel 4 weeks 
injection later 
Massive amount of effusion 11 (78.6) 
Moderate amount of effusion 3 (21.4) 1 (7.1) 
Small amount of effusion 3 (21.4) 3 (21.4) 3 (21.4) 
Costophrenic angle blunting 10 (42.9) 4 (28.6) 7 (50) 
Localized loculated effusion 5 (35.7) 
Multiple loculated effusion 1 (7.1) 5 (35.7) 6 (42.9) 
Interlobar effusion 1 (7.1) 2 (14.3) 2 (14.3) 
*Massive amount of effusion, volume of effusion more than half of hemithorax with mediastinal 
shift; moderate amount of effusion, volume of effusion between one-third and one-half of 
hemithorax; small amount of effusion, volume of effusion less than one-third of effusion and more 
than only costophrenic angle blunting. 
treatment owing to disease progression, Facial flushing Fourteen of the 15 patients were assessable for response 
occurred in six patients (40%) and five were women. The of effusion control at the end of the 4th week (Table 5). The 
facial flushing occurred within 24 h and subsided within remaining patient died of progressive disease during the 
72 h after paclitaxel treatment. Paclitaxel fluid leakage into first 4 weeks after entry on study. This early death did 
the subcutaneous space of the chest wall occurred in one not seem to be related to the intrapleural chemotherapy. 
patient. This patient was the only patient who suffered from Four patients had a CR and nine patients had a PR at 
grade 4 neutropenia with fever. Tumour seeding along the 4 weeks for an overall initial objective response rate of 
pig-tail tunnel with moderate pain occurred in one patient. 86.7% of effusion control (13 of 15; 95% confidence 
The most frequent late effect or complication of intra- interval, 69.5-100%). Among the 14 patients assessable 
pleural paclitaxel injection was pleural thickening with at 4 weeks, this represents an effusion control rate of 
loculated effusion which occurred in 11 of 14 patients 92.9% (13 of 14; 95% confidence interval, 794100%). 
(78.6%) in follow-up chest CT scan, radiography and/or This also meant that 92.9% of patients had their 
sonography 4 weeks after intrapleural paclitaxel injection dyspnoea improved after intrapleural paclitaxel treatment. 
(Table 4). The loculated effusions were usually complex, Fourteen patients were assessable for response at 
septated effusions with marked thickening of pleura, found 2 months after treatment. Among them, four patients 
by sonography and/or CT scan. had a CR and six patients had a PR for an overall 
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TABLE 5. Response of malignant pleural effusion after paclitaxel intrapleural therapy 
Months 
1 
2 
3 
No. of evaluable 
patients 
14 
14 
13 
CR (u/o) PR (%) 
4 (286) 9 (64.3) 
4 (28.6) 6 (428) 
4 (308) 5 (38.4) 
Overall 
response (%) 
13 (92.9) 
10 (71.4) 
9 (69.2) 
Failure (%) 
1 (7.1) 
4 (28.6) 
4 (30.8) 
objective response rate of 71.4% of effusion control in 14 
assessable patients. Overall response rate of effusion 
control in 13 evaluable patients at 3 months after treatment 
was 69.2% (Table 5). 
Regarding tumour response to intrapleural paclitaxel 
treatment, one patient had a PR of his measurable lesion at 
4 weeks, and three patients had an MR. Among 14 assess- 
able patients, no progressive disease of tumour lesions was 
noted at 4 weeks after treatment. 
Discussion 
Malignant pleural effusions are recognized as a distressing 
common problem of advanced cancer. Lung cancer is the 
leading cause of malignant effusions. The presence of a 
malignant pleural effusion in lung cancer indicates at least 
locally advanced disease (stage IIIb, IV). The prognosis of 
these patients is poor. 
The most practical approach today for the clinician to 
treat a patient with a symptomatic malignant effusion is still 
controversial. The traditional management of malignant 
pleural effusions has been focused on the control of the 
effusion for the palliation of symptoms. Many agents have 
been used and no single agent has been proved to be 
entirely satisfactory. They include the intrapleural admin- 
istration of talc, C. parvum, tetracycline, tetracycline deriva- 
tives, bleomycin, mechlorethamine, doxorubicin, cisplatin, 
cytarabine, etoposide, fluorouracil, mitomycin-C, inter- 
feron, interleukin-2, OK-432 etc (6,8,10,11, 20-34). Tetra- 
cycline has emerged as the agent of choice because it is at 
least as effective as all the others and is easily available and 
inexpensive (6,8,9,32). However, parenteral tetracycline has 
become unavailable owing to more stringent manufacturing 
requirements. Minocycline and doxycycline, with success 
rates of more than 70%, appear to be effective tetracycline- 
replacement agents in recent studies (6,26). Because of the 
lack of a large-scale randomized study, difficulties with 
study design and inconsistencies in evaluation of patients in 
different studies, none has been clearly proved superior to 
other agents. Doxycycline, bleomycin, and talc are effective 
sclerosing agents most frequently used in recent years 
(35-37). It was found that bleomycin is superior to or as 
effective as tetracycline in previous randomized trials 
(30,35,38). In two small randomized studies comparing the 
efficacy of talc with either tetracycline or bleomycin, it was 
found that talc appeared to be more effective than tetra- 
cycline and bleomycin (39,40). A phase II clinical trial with 
multiple arms including talc, tetracycline and bleomycin 
also showed significant superior response in talc treatment 
compared with tetracycline and bleomycin. In this study, it 
was found that 97% patients had a successful pleurodesis at 
30 days and 95% at 90 days. It was 64% and 70% in 30 days 
and 90 days respectively in the bleomycin group. It was 
only 33”/0 and 47% in 30 days and 90 days respectively in 
tetracycline-treated patients (41). The expected response 
rate for freedom from recurrence of a symptomatic effusion 
1 month after treatment is 84%, 69% and 96% for bleo- 
mycin, tetracycline and talc respectively (36). However, the 
administration of talc is considered to be more complicated 
and with a higher incidence of morbidity than simple 
pleurodesis with bleomycin or tetracycline (35,36). When 
comparing with our studies, it was found that paclitaxel- 
treated patients had a 92.9% response rate 1 month after 
treatment. This response rate was better than the expected 
response rate of bleomycin and tetracycline. However, it 
was still lower than that for talc treatment. 
The use of intrapleural chemotherapy has the potential 
advantage of treating the underlying malignancy and con- 
trolling the malignant effusion. The drug level in the pleural 
cavity can be many-fold higher than the systemic level. In 
theory, such an approach could maximize the treatment 
effect of local disease while minimizing systemic toxicity. 
However, it has several limitations. It requires good disper- 
sion throughout the whole pleural cavity and it can 
penetrate into the tumour to a distance of only a few 
millimeters (8,9,11). Patients who have bulky tumours or 
intrapleural adhesions are unlikely to benefit from this 
treatment modality. Bleomycin is an effective sclerosing 
agent with few side-effects, but it does not have good 
antineoplastic activity in the malignancies that commonly 
cause pleural effusion (8,9,27,30,35). As more effective 
anti-cancer drugs have been found in recent years, there is 
an increasing interest in using drugs that are thought to act 
primarily by cytotoxicity rather than by sclerosis. 
Paclitaxel is a new chemotherapeutic agent with activity 
in NSCLC. From our data, paclitaxel is highly effective in 
controlling malignant effusion from NSCLC. This result is 
most likely better than previous reports involving intra- 
pleural chemotherapy, including bleomycin (6,8,32,33). In 
addition, no patient suffered from progression of disease 
during 4 weeks follow-up after paclitaxel treatment. More 
importantly, there was one out of 14 patients who had more 
than 50% primary tumour lesion shrinkage. This means 
that intrapleural paclitaxel injection still had a systemic 
anti-tumour effect. The exact mechanisms of pleurodesis 
caused by paclitaxel on malignant pleural effusion of 
NSCLC were not clear. Intrapleural paclitaxel treatment 
probably had both anti-cancer effect and sclerosing effect. 
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The anti-tumour effect was supported by disappearance or 
marked degeneration of malignant cells from the effusion 
after paclitaxel treatment in patients who had effusion 
cytology follow-up. The sclerosing effect was supported by 
the observation that paclitaxel can cause chest pain after 
instillation and produce pleural thickening and adhesions. 
The toxicities of paclitaxel treatment seen in this study 
are somewhat different from those found when it is admin- 
istered systematically. Facial flushing, chest and/or shoul- 
der pain and fever are more commonly seen than in those 
patients receiving systemic paclitaxel treatment. However, 
no serious .adverse, reactions were seen. Another problem 
concerning intraplenral paclitaxel treatment is that the cost 
is much higher in patients receiving paclitaxel treatment 
than chemical pleurodesis alone, such as minocycline or 
doxycycline. 
When considering cost-effectiveness, paclitaxel is expen- 
sive at a cost of approximately $1200 for a 70 kg person of 
normal surface area. This cost is higher than those of 
doxycycline or minocycline pleurodesis. The cost will be 
even higher when the hospitalization fee is also considered. 
Therefore, use of paclitaxel for the purpose of pleurodesis 
only has a cost disadvantage. However, the major short- 
coming of our study is the limited number of patients 
tested. Given the small number of patients tested, it needs 
to be more cautious when drawing the conclusions. 
Overall, paclitaxel appears to be a useful agent for the 
treatment of malignant pleural effusions. Because of its low 
systemic side-effects and high local efficacy, it can be 
considered to be used in combination with systemic chemo- 
therapy or radiotherapy in managing NSCLC patients with 
malignant pleural effusions. 
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